Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases

Verfasser / Beitragende:
[Naoki Izawa, Yusuke Onozawa, Tomomi Hikosaka, Satoshi Hamauchi, Takahiro Tsushima, Akiko Todaka, Nozomu Machida, Yutaka Haraguchi, Hirofumi Ogawa, Tetsuo Nishimura, Masahiro Nakagawa, Tomohito Fuke, Yoshiyuki Iida, Tomoyuki Kamijo, Tetsuro Onitsuka, Narikazu Boku, Hirofumi Yasui, Tomoya Yokota]
Ort, Verlag, Jahr:
2015
Enthalten in:
International Journal of Clinical Oncology, 20/3(2015-06-01), 455-462
Format:
Artikel (online)
ID: 605491038
LEADER caa a22 4500
001 605491038
003 CHVBK
005 20210128100508.0
007 cr unu---uuuuu
008 210128e20150601xx s 000 0 eng
024 7 0 |a 10.1007/s10147-014-0749-4  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10147-014-0749-4 
245 0 0 |a Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases  |h [Elektronische Daten]  |c [Naoki Izawa, Yusuke Onozawa, Tomomi Hikosaka, Satoshi Hamauchi, Takahiro Tsushima, Akiko Todaka, Nozomu Machida, Yutaka Haraguchi, Hirofumi Ogawa, Tetsuo Nishimura, Masahiro Nakagawa, Tomohito Fuke, Yoshiyuki Iida, Tomoyuki Kamijo, Tetsuro Onitsuka, Narikazu Boku, Hirofumi Yasui, Tomoya Yokota] 
520 3 |a Background: We evaluated the efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC) with a high risk of distant metastases compared with CRT alone. Methods: We retrospectively analyzed 29 HNSCC patients with clinical nodal stage N2c, N3, or N2b disease and supraclavicular lymph node metastases receiving CRT alone (CRT group; n=16) or TPF induction chemotherapy followed by CRT (TPF group; n=13) between April 2008 and May 2012. Results: The median follow-up periods were 14.5 (range 5.0-65.0) and 25.0(range 14.0-32.0) months for CRT and TPF groups, respectively. A greater proportion of patient characteristics in the CRT group had advanced T and N stages. The overall response rate to induction TPF was 50.0%; grade 3-4 toxicities included neutropenia, febrile neutropenia, anorexia, and hyponatremia. Complete response rates after CRT completion were 55.5% in the TPF and 42.9% in the CRT group; median overall survival was not reached in the TPF group and was 14.0months in the CRT group (p=0.037). Multivariate analysis revealed that induction TPF and T stage were independent prognostic factors [hazard ratio (HR)=0.196; 95% confidence interval (CI) 0.043-0.898; p=0.036, HR=9.966; 95% CI 2.270-43.75; p=0.002, respectively). Conclusion: TPF followed by CRT is tolerated and may be an option for the treatment of locally advanced stage N2c, N3, or N2b HNSCC. 
540 |a Japan Society of Clinical Oncology, 2014 
690 7 |a TPF  |2 nationallicence 
690 7 |a Induction chemotherapy  |2 nationallicence 
690 7 |a Chemoradiotherapy  |2 nationallicence 
700 1 |a Izawa  |D Naoki  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Onozawa  |D Yusuke  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Hikosaka  |D Tomomi  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Hamauchi  |D Satoshi  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Tsushima  |D Takahiro  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Todaka  |D Akiko  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Machida  |D Nozomu  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Haraguchi  |D Yutaka  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Ogawa  |D Hirofumi  |u Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Nishimura  |D Tetsuo  |u Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Nakagawa  |D Masahiro  |u Division of Plastic and Reconstructive Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Fuke  |D Tomohito  |u Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Iida  |D Yoshiyuki  |u Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Kamijo  |D Tomoyuki  |u Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Onitsuka  |D Tetsuro  |u Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Boku  |D Narikazu  |u Division of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, 216-8511, Kawasaki, Japan  |4 aut 
700 1 |a Yasui  |D Hirofumi  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
700 1 |a Yokota  |D Tomoya  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
773 0 |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/3(2015-06-01), 455-462  |x 1341-9625  |q 20:3<455  |1 2015  |2 20  |o 10147 
856 4 0 |u https://doi.org/10.1007/s10147-014-0749-4  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10147-014-0749-4  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Izawa  |D Naoki  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Onozawa  |D Yusuke  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Hikosaka  |D Tomomi  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Hamauchi  |D Satoshi  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Tsushima  |D Takahiro  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Todaka  |D Akiko  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Machida  |D Nozomu  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Haraguchi  |D Yutaka  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ogawa  |D Hirofumi  |u Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Nishimura  |D Tetsuo  |u Division of Radiation Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Nakagawa  |D Masahiro  |u Division of Plastic and Reconstructive Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Fuke  |D Tomohito  |u Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Iida  |D Yoshiyuki  |u Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kamijo  |D Tomoyuki  |u Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Onitsuka  |D Tetsuro  |u Division of Head and Neck Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Boku  |D Narikazu  |u Division of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, 216-8511, Kawasaki, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Yasui  |D Hirofumi  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Yokota  |D Tomoya  |u Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi Sunto-gun, 411-8777, Shizuoka, Japan  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/3(2015-06-01), 455-462  |x 1341-9625  |q 20:3<455  |1 2015  |2 20  |o 10147